## Alfa Aesar

## Organosilanes

Organosilanes are widely used in organic chemistry, particularly as protecting groups ${ }^{1,2}$, derivatisation reagents ${ }^{3}$, reducing agents ${ }^{4}$ and synthetic intermediates. The extensive Alfa Aesar ${ }^{\text {TM }}$ portfolio has been developed to facilitate all of these applications.

## Silicon protecting groups

Silylating agents are mostly used to protect alcohols and phenols, but have also found application in the protection of amines, carboxylic acids, amides, thiols and alkynes. Replacement of the Trimethylsilyl (TMS) group by tert-butyl gives a tert-butyldimethylsilyl (TBDMS) group, which is considerably more stable than the TMS group.

Within the Alfa Aesar range we offer tert-Butyldimethylchlorosilane (TBDMSCI) [A13064] as well as other common silyl protecting groups including Trimethylsilyl chloride (TMSCI) [A13651]; Triethylsilyl chloride (TESCI) [A15547] and Trisopropylsilyl chloride (TIPSCI) [A17376].

## Derivatization

Derivatization of a compound by reaction with a silylating agent is of particular use in gas chromatography (GC) analysis. Molecules containing functional groups such as carboxylic acid, hydroxyl, amine, thiol and phosphate, which may be difficult to analyse by GC, can be readily converted into silylated derivatives which are generally less polar, more volatile and have greater thermal stability and are therefore more suitable for GC analysis.
N,O-Bis(trimethylsily)ltrifluoroacetamide ${ }^{5}$, (BSTFA) [43429] is a powerful analytical silylation reagent. The by-products and the reagent itself are highly volatile so cause minimal interference with the GC analysis.


## Synthetic intermediates

There is a growing need for orgnosilanes in the field of silicon containing organic polymers, whose potential applications include electronic and optical materials, catalysts and coatings. ${ }^{6}$ Hydrolytic condensation of trifunctional silanes yields silsesquioxanes, where each silicon atom is bound to an average of one and a half oxygen atoms and to one hydrocarbon group. Among various types of silsesquioxanes, polyhedral oligomeric silsesquioxane (POSSTM) reagents offer a unique opportunity for preparing hybrid organic-inorganic materials with the inorganic structural units truly molecularly dispersed within the nanocomposites.


Under the Alfa Aesar brand we have several trichlorosilanes which are useful precursors to silsesquioxanes, with examples such as [A11256], [A15732], [B23107] \& [B23753]. All follow the general formula shown below.

$$
\mathrm{RSix}_{3} \xrightarrow[\text { Solvent }]{\mathrm{H}_{2} \mathrm{O}}\left[\mathrm{RSiO}_{3 / 2}\right]_{n}
$$

## Organosilicon alkynes

Alkynes are highly reactive and the triple bond can exert remarkable effects on the rest of the molecule through a combination of characteristic properties. A number of new organosilicon alkynes derivatives are now available through Alfa Aesar, and many have already been extensively cited in scientific literature.

Researchers at MIT have proposed a two-stage "tandem strategy" for the synthesis of benzofused nitrogen heterocycles, via a benzannulation based on the reaction of cyclobutenones with ynamides derived from H53375. ${ }^{7}$ Several groups have described the development of a rhodium-catalyzed asymmetric isomerization of racemic à-arylpropargyl alcohols to á-chiral indanones ${ }^{8}$ of H53426. Similarly, cobalt-catalyzed carbocylization has been used for the synthesis of indenols and indenes using H53517, in high yield and excellent regioselectivity. ${ }^{9}$ In a synthetic approach toward the natural product cytostatin, an inhibitor of protein phosphatase 2A, the subunit of cytostatin has been prepared in a six steps from H53517. ${ }^{10} \mathrm{~A}$ convenient preparation of functionalized benzo[c]selenophenes involves treatment of isoselenocyanate with lithiated o-bromoethynylbenzenes (H53402). ${ }^{11}$ Recent patents have shown that H53487 to be effective component of pharmaceutically active compounds such as potential metalloproteinase inhibitors, ${ }^{12}$ in the treatment of cystic fibrosis, ${ }^{13}$ or the treatment of vascular diseases. ${ }^{14}$

A selection of the organosilicon alkynes offered by Alfa Aesar are listed below.

| VWR <br> Cat. No. | Description | Size | CAS No. |
| :--- | :--- | :--- | :--- |
| H53402 | (2-Bromophenylethynyl)trimethylsilane, $98 \%$ | $1 \mathrm{~g}, 5 \mathrm{~g}, 25 \mathrm{~g}$ | $38274-16-7$ |
| H 53515 | 1-Chloro-5-triethylsilyl-4-pentyne, $97 \%$ | $5 \mathrm{~g}, 25 \mathrm{~g}$ | $174125-30-5$ |
| H53393 | 1-Chloro-5-trimethylsilyl-4-pentyne, $97 \%$ | $5 \mathrm{~g}, 25 \mathrm{~g}$ | $77113-48-5$ |
| H53375 | 1-lodo-2-(trimethylsilyl)acetylene, $97 \%$ | $1 \mathrm{~g}, 5 \mathrm{~g}, 25 \mathrm{~g}$ | $18163-47-8$ |
| H53426 | 1-Phenyl-3-trimethylsilyl-2-propyn-1-ol, $98 \%$ | $5 \mathrm{~g}, 25 \mathrm{~g}$ | $89530-34-7$ |
| H53488 | 1-Triethylsilyl-4-triethylsilyloxy-1-butyne, $97 \%$ | $5 \mathrm{~g}, 25 \mathrm{~g}$ | $160194-28-5$ |
| H53423 | 1-Trimethylsilyl-1-pentyne, $98 \%$ | $5 \mathrm{~g}, 25 \mathrm{~g}, 100 \mathrm{~g}$ | $18270-17-2$ |
| H 53436 | 1-Trimethylsilyl-1,4-pentadiyne, $98 \%$ | $1 \mathrm{~g}, 5 \mathrm{~g}, 25 \mathrm{~g}$ | $71789-10-1$ |
| H53397 | 3-(Trimethylsilyl)propiolaldehyde diethyl acetal, $97 \%$ | $5 \mathrm{~g}, 25 \mathrm{~g}$ | $87219-80-5$ |
| H53380 | 3-(Trimethylsilyl)propiolic acid, $97 \%$ | $1 \mathrm{~g}, 5 \mathrm{~g}, 25 \mathrm{~g}$ | $5683-31-8$ |
| H53376 | 4-Trimethylsilyl-3-butyn-1-ol, $98 \%$ | $5 \mathrm{~g}, 25 \mathrm{~g}$ | $2117-12-6$ |
| H53457 | 5-Trimethylsilyl-4-pentyn-1-ol, $97 \%$ | $5 \mathrm{~g}, 25 \mathrm{~g}$ | $13224-84-5$ |
| H53487 | Cyclopropyl(trimethylsilyl)acetylene, $97 \%$ | $5 \mathrm{~g}, 25 \mathrm{~g}$ | $81166-84-9$ |
| H53517 | Ethyl 3-(trimethylsilyl)propiolate, $98 \%$ | $1 \mathrm{~g}, 5 \mathrm{~g}, 25 \mathrm{~g}$ | $16205-84-8$ |
| H53494 | tert-Butyldimethylsilylacetylene, $98 \%$ | $1 \mathrm{~g}, 5 \mathrm{~g}, 25 \mathrm{~g}$ | $86318-61-8$ |
| H53405 | Triisopropylsilylacetylene, $97 \%$ | $5 \mathrm{~g}, 25 \mathrm{~g}$ | $89343-06-6$ |

Full product listing is available online.

For your convenience the products listed throughout the brochure are detailed below.

## Silicon protecting groups

| VWR <br> Cat. No. | Description | Size | CAS No. |
| :--- | :--- | :--- | :--- |
| A15547 | Chlorotriethylsilane, $98+\%$ | $10 \mathrm{~g}, 50 \mathrm{~g}, 250 \mathrm{~g}$ | $994-30-9$ |
| A17376 | Chlorotriisopropylsilane, $97+\%$ | $10 \mathrm{~g}, 50 \mathrm{~g}, 250 \mathrm{~g}$ | $13154-24-0$ |
| AA13651 | Chlorotrimethylsilane, $98+\%$ | $25 \mathrm{ml}, 100 \mathrm{ml}, 500 \mathrm{ml}$ | $75-77-4$ |
| A13064 | tert-Butyldimethylchlorosilane, $97 \%$ | $5 \mathrm{~g}, 25 \mathrm{~g}, 100 \mathrm{~g}$ | $18162-48-6$ |

Full product listing is available online.

## Synthetic intermediates

| VWR <br> Cat. No. | Description | Size | CAS No. |
| :--- | :--- | :--- | :--- |
| B23107 | Methyltrichlorosilane, $97 \%$ | $100 \mathrm{~g}, 500 \mathrm{~g}$ | $75-79-6$ |
| A11256 | n-Butyltrichlorosilane, $97+\%$ | $25 \mathrm{~g}, 100 \mathrm{~g}$ | $7521-80-4$ |
| A15732 | n-Octadecyltrichlorosilane, $95 \%$, cont. $5-10 \%$ branched isomers | $50 \mathrm{~g}, 250 \mathrm{~g}, 1 \mathrm{~kg}$ | $112-04-9$ |
| B23753 | n-Octyltrichlorosilane, $97 \%$ | $25 \mathrm{~g}, 100 \mathrm{~g}, 500 \mathrm{~g}$ | $5283-66-9$ |

Full product listing is available online.

## Alfa Aesar

## References

1 Greene,T.; Wuts, P. G. M. Protecting Groups in Organic Synthesis. 2nd Ed. Wiley, New York. 1991.
2 Kocienski, P. J. Protecting Groups. 3rd Ed. Thieme: Stuttgart. 1994.
3 Blau, K.; Halket J. Handbook of Derivatives for Chromatography. 2nd Ed. J. Wiley and Sons, New York. 1993.
4 Chatgilialoglu, C. Organosolanes as radical-based reducing agents in synthesis. Acc. Chem. Res. 1992, 25, 188.
5 Stalling, D. L.; et al., Biochem. Biophys. Res.Commun. 1968, 31, 616.
6 Hartmann-Thompson, C. (Ed.); Applications of Polyhedral Oligomeric Silsesquioxanes - Advances in Silicon Science, Vol. 3; 1st Ed. 2011.
7 (a) Mak, X. Y.; Crombie, A. L.; Danheiser, R. L. J. Org. Chem. 2011, 76, 1852.
(b) Kohnen,A. L.; Xiao,Y. M.; Tin, Y. L.; Dunetz, J. R.; Danheiser, R. L. Tetrahedron. 2006, 62, 3815.

8 (a) Shintani, R.; Okamoto, K.; Hayashi, T. J. Am. Chem. Soc. 2005, 127, 2872.
(b) Yamabe, H.; Mizuno, A.; Kusama, H.; Iwasawa, N. J. Am. Chem. Soc. 2005, 127, 3248.
(c) Kundu, K.; McCullagh, J. V.; Morehead Jr., A. T. J. Am. Chem. Soc. 2005, 127, 16042.

9 Chang, K. -J.; Rayabarapu, D. K.; Cheng, C.-H. J. Org. Chem. 2004, 69, 4781.
10 Salit, A.-F.; Meyer, C.; Cossy, J.; Delouvrie, B.; Hennequin, L. Tetrahedron, 2008, 64, 6684.
11 Kaname, M.; Sashida, H. Tetra. Lett. 2011, 52, 3279.
12 Wyeth, Patent: US2005/143422 A1, 2005.
13 Vertex Pharmaceuticals Incorported, Patent: US2011/98311 A1, 2011.
14 Dhar, T.G M.; Xiao, H.-Y; Watterson, S. H.; Ko, S. S.; Dyckman, A. J.; Langevine, C. M.; Das, J.; Cherney, R. J. Bristol-Myers Squibb Company Patent: WO2011/59784 A1, 2011.

